Business Context and Reporting Period
Company: Daxor Corporation (DXR)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 1995
Business Overview: Daxor operates in the medical technology and services sector, primarily through its Idant Laboratory division. Core operations include long-term cryopreservation of human semen (sperm banking) and autologous blood banking. The Company also develops the Blood Volume Analyzer (BVA-100), a diagnostic instrument for measuring total blood volume.
Key Financial Metrics
| Metric | 1995 | 1994 |
|---|---|---|
| Total Revenues | $4,748,935 | $4,587,135 |
| Operating Revenues | $1,863,552 | $1,844,418 |
| Dividend Income | $2,209,962 | $2,157,735 |
| Net Income | $1,287,115 | $1,808,135 |
| Net Income Per Share | $0.26 | $0.35 |
| Total Assets | $37,744,621 | $35,012,638 |
| Shareholders' Equity | $32,052,831 | $29,199,180 |
| Working Capital | $31,598,345 | $28,739,806 |
| Short-Term Debt | $1,536,609 | $3,864,605 |
| Cash and Equivalents | $1,987 | $59,962 |
Note: The Company maintains a significant portfolio of marketable securities ($35.7M fair value) which generates substantial dividend income and unrealized gains, heavily influencing total revenue and equity figures.
Material Changes vs. Prior Period
- Profitability Decline: Net income decreased by approximately 29% to $1.29 million in 1995 compared to $1.81 million in 1994. This decline is attributed to increased legal fees and operational restrictions.
- Revenue Composition: While total revenue increased slightly, operating revenue growth was minimal. The Company relies heavily on investment income (dividends and capital gains), which comprised roughly 56% of total revenue in 1995.
- Debt Reduction: Short-term debt decreased significantly from $3.86 million in 1994 to $1.54 million in 1995, improving the liquidity position.
- Operational Restriction: On August 21, 1995, the New York State Department of Health (NYSDOH) revoked the Company's licenses without a hearing. Consequently, the Idant division has been operating on a "partial storage basis only," unable to process new specimens or ship donor semen, directly impacting revenue potential.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
Management anticipates that a successful resolution of ongoing legal appeals will restore full laboratory functionality. The Company plans to expand into a nationwide network of autologous blood banks and market the BVA-100 instrument via sales and leases. However, the commercial launch of the BVA-100 is currently delayed due to the unavailability of the required isotope (Albumin I-131) from an FDA-approved manufacturer (Iso-Tex Diagnostics).
Material Risks and Contingencies
- Regulatory and Legal Actions: The Company is engaged in multiple lawsuits against the NYSDOH and the New York Blood Center, including a $100 million RICO/Anti-trust suit alleging predatory monopolistic practices. The outcome of these suits is critical to the Company's ability to operate its blood and sperm banks.
- Licensing Status: The revocation of licenses in August 1995 remains a primary risk. While a class action suit has temporarily enjoined the destruction of client specimens, the Company cannot accept new deposits or ship donor semen until licenses are reinstated.
- Supply Chain Dependency: The BVA-100 product launch is contingent upon FDA approval for Iso-Tex Diagnostics to manufacture the necessary isotope. Approval is expected in 1996 but is not guaranteed.
- Market Competition: The blood banking industry is described as a monopoly or semi-monopoly controlled by tax-exempt organizations (e.g., Red Cross, New York Blood Center) that actively oppose Daxor's frozen autologous blood model.
Investor Verification Checklist
- License Reinstatement: Verify the current status of the appeals regarding the August 1995 NYSDOH license revocation and the timeline for potential reinstatement.
- Isotope Approval: Confirm the FDA approval status of Iso-Tex Diagnostics for Albumin I-131, which is the critical path for the BVA-100 revenue stream.
- Legal Exposure: Assess the potential financial impact of the $100 million RICO/Anti-trust lawsuit and the defense costs associated with multiple state and federal proceedings.
- Investment Portfolio Reliance: Evaluate the sustainability of the business model given that over 50% of revenue is derived from investment income rather than core medical services.
- Cash Position: Monitor the low cash balance ($1,987) relative to operating expenses and the reliance on the securities portfolio for liquidity.